| INTRODUC TI ON
The development of antibodies against donor human leukocyte antigens (donor specific antibodies, DSA) after lung transplantation has been associated with antibody-mediated rejection (AMR), chronic lung allograft dysfunction (CLAD) and patient mortality. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, there are many open questions concerning DSA and AMR treatment. 10 Different protocols have been used, making any conclusion about treatment efficacy difficult. [11] [12] [13] [14] [15] [16] [17] Treatment of clinical AMR has shown suboptimal efficacy, since the graft dysfunction may not be reversible anymore. 12, 17 Since March 2013, at our institution, patients who developed DSA early after transplantation (eDSA) have been treated with a protocol based on successive infusion of IgA-and IgM-enriched intravenous human immunoglobulins (IgGAM, Pentaglobin, Biotest AG, Dreieich, Germany). In our experience, treated patients showed good eDSA clearance and short-term graft survival that was comparable to survival of patients without eDSA. 14 This retrospective study presented our 4-year experience of early DSA treatment with IgGAM in lung transplantation. We compared outcomes between patients with eDSA treated with IgGAM and patients without eDSA.
| ME THODS

| Patients
The in-hospital and follow-up records of patients who underwent lung transplantation at our institution between March 2013 and November 2017 were retrospectively reviewed.
Patients who showed eDSA after transplantation and were treated with IgGAM formed the eDSA + /IgGAM + group (case group).
The outcomes of eDSA + /IgGAM + patients were compared to the outcomes of patients who did not show eDSA after transplantation (eDSA − patients, control group).
Patients, who showed eDSA and were treated without IgGAM (eDSA + /IgGAM − patients), and the few patients who showed eDSA but were not treated at all (eDSA + /no-treatment patients), were excluded from the study. However, their results were reported in the supporting information section.
Follow-up ended on November 1, 2017 and was 100% completed.
The hospital ethical review board waived the need of patient consent to the study, since all patients had given their consent to handle their personal data for research purposes at the time of listing to lung transplantation. In addition, in eDSA + /IgGAM + patients, a patient consent was obtained to perform the additional DSA controls at follow-up.
| Variable definition
The present study focused on the treatment of early DSA, which were defined as DSA, which were detected during initial hospitalization after lung transplantation, before hospital discharge. eDSA clearance was defined as absence of DSA in two consecutive Luminex-based SPA (LIFECODES, Immucor Transplant Diagnostics, Inc., Stamfort, CT) controls. DSA recurrence was defined as a renewed positivity of previously cleared DSA at Luminex-based SPA control.
The definitions of other variables and outcomes are reported elsewhere. 3, 13, 14, [18] [19] [20] Details on patient management after transplantation at our institution are reported in the supporting information section of this manuscript. 3, 13, 14 
| eDSA detection protocol
All patients were screened for anti-HLA antibodies at the time of listing to lung transplantation, and for eDSA, immediately before lung transplantation, on day 14 and before hospital discharge or upon indication. In the Luminex analysis, a low threshold of 1000 mean fluorescence index (MFI) was used to detect eDSA.
At follow-up, in eDSA + /IgGAM + patients, Luminex-based DSA controls were performed at the beginning of each IgGAM treatment session and, after treatment end, every 6 months. In eDSA − as well as excluded eDSA + /IgGAM − and eDSA + /no-treatment patients, DSA were not regularly assessed, but only upon indication.
| eDSA treatment protocols
In March 2013, an IgGAM-based treatment protocol replaced the previous rather ineffective eDSA treatment protocol which had been based only on therapeutic plasmapheresis (tPE) and a single dose of anti-CD 20 antibody (Rituximab). 13, 14 Pentaglobin was used, since it has been demonstrated that its IgA and IgM components conferred additional immunomodulatory and antimicrobial effects. 21 eDSA treatment with IgGAM represents an off-label use of IVIG.
Treatment was usually performed preemptively, since most of the patients showed only serologic evidence of eDSA (possible subclinical AMR 9 ). In those patients with graft dysfunction, dysfunction was defined as worsening of blood oxygenation and/or lung function tests, unexplained by concomitant infection. In this case, diagnosis of definite clinical AMR was not made, since transbronchial biopsies were usually not performed early after transplantation for safety reasons (possible clinical AMR 9 ).
IgGAM therapy consisted of a first infusion of 2 g/kg of IgGAM followed by additional infusions of 0.5 g/kg of IgGAM every 4 weeks until eDSA clearance or for a maximum of 6 months. Other procedures and drugs, comprising 3 distinct successive treatment protocols, were added to the first IgGAM infusion ( Figure 1 ).
More treatment details are reported in the supporting information section. Survival estimates along with freedom from endpoints were calculated by the product-limit method of Kaplan-Meier. Differences between groups were quantified using the log-rank test.
| Statistics
In order to account for the influence on outcomes of the variables which showed a statistical significant difference (P ≤ .05) among in- P-values ≤ .05 were considered significant. 
| RE SULTS
| Patient groups
| eDSA
In case group, 21 (16%) patients showed pre-formed eDSA. The remaining 107 (84%) patients developed de-novo eDSA. eDSA were more often against donor HLA class II than I antigens (81% vs. 25%, Table 3 ). Twelve (9%) patients showed eDSA against both HLA class antigens. Median time to eDSA positivity was 14 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days. Before treatment start, median MFI value was 4279 (2264-9983). Median cumulative MFI value was 4961 (2290-11 197).
| eDSA treatment and IgGAM side effects
Treatment was performed preemptively in 110 (86%) patients. The 
| eDSA clearance
eDSA clearance is reported in Figure 3 and Cystic fibrosis 24 (19) 99 (22) .44
Pulmonary hypertension 15 (12) 17 (4) <.001
Re-transplant 11 (9) 32 (7) .56
Other 5 (4) 28 (6) .32
Associated pulmonary artery hypertension 
| Outcomes
Median follow-up was 24 (11-40) months and did not differ between eDSA + /IgGAM + and eDSA − patients (P = .76). Outcomes of eDSA + / IgGAM + versus eDSA − did not show significant statistical differences between groups (Table 6 and Figure 4A-D) . However, freedoms from biopsy confirmed rejection ( Figure 4B ) and from pulsed steroid therapy ( Figure 4C ) at 6 months after transplantation were higher in eDSA + /IgGAM + than eDSA − patients. These results were confirmed after propensity score matching and stratification according to quintiles of propensity scores (Tables S3-S6 ).
eDSA + /IgGAM + patients showed better graft survival (P = .005) and freedom from retransplant (P = .02) than excluded eDSA + patients (Table S7) , and particularly better freedom from retransplant (P = .003) than eDSA + /no-treatment patients (Table S8 ). However, this could have been confounded by the small number of excluded patients.
In eDSA + /IgGAM + patients, outcomes did not differ after stratification according to presence of preformed versus de novo eDSA, use of tPE or immunoabsorption, use of treatment protocol 1 versus 2, and eDSA clearance at treatment end (Tables S9, S10 , S11, S12, Anti-HLA I 26 (20) 83 (18) .62
Anti-HLA II 40 (31) 86 (19) .003
Anti-HLA I + anti-HLA II 9 (7) 24 (5) . respectively). However, eDSA + /IgGAM + patients who had a negative crossmatch, did not have graft dysfunction at treatment time, and received Rituximab, had better graft survival (Tables S13, S14, S15, respectively).
Finally, outcomes were similar between a small number of eDSA + /no-treatment patients and eDSA − patients, except for a higher incidence of retransplant in eDSA + /no-treatment patients (Table S16) .
Median forced respiratory volume in 1 second (FEV 1 ) values (% predicted) did not differ between eDSA + /IgGAM + ver- 
| D ISCUSS I ON
This study represents the largest single-centre case series on treatment of early DSA in lung transplantation published so far. [11] [12] [13] [15] [16] [17] IVIG are a consolidated component of AMR treatment protocols in renal transplantation. 23, 24 In lung transplantation, conversely, there is no consensus on when and how AMR must be treated. [11] [12] [13] [14] [15] [16] [17] In the first published case series on preemptive DSA treatment with IVIG after transplantation, Hachem et al showed a DSA clearance of 65% at treatment end. Outcomes were worse in patients who did not clear DSA than in patients who did. 11 All these studies reconfirm that current treatment protocols are ineffective in cases of AMR with established graft dysfunction.
Therefore, at our institution, we treat patients as soon as eDSA are detected, mainly preemptively (possible subclinical AMR). In our opinion, eDSA represent just the early measurable part of general allosensitization of host versus graft. 25 We observed that survival and outcomes were similar in treated patients versus patients without eDSA. In accordance with the previously reported literature, those patients with graft dysfunction (possible clinical AMR) showed worse survival and eDSA clearance than patients with only eDSA (possible subclinical AMR).
Freedom from biopsy confirmed rejection and from pulsed steroid therapy were higher during treatment time (Figure 4B,C In our study, freedom from infection was similar among groups during treatment, but worsened thereafter in previously treated patients. This trend may be due to a late effect of Rituximab.
During the study period, we developed three different IgGAMbased protocols to treat eDSA, looking for the most appropriate therapy. In fact, therapies of AMR may also provoke side effects, and the benefit of treatment must be carefully evaluated against the risk of side effects, particularly in asymptomatic patients with eDSA. We usually combined IgGAM with a single dose of Rituximab and, in some patients, with tPE or immunoabsorption. No difference was found in clearance and outcomes between protocol 1 and 2. The addition of 2 immunoabsorptions in all patients with eDSA did not add any benefit and did not reduce treatment time. patients, yet freedom from CLAD and re-transplant were worse in untreated patients. Moreover, in a recent publication, spontaneous DSA clearance was observed in 34.7% of patients and was associated with a lower risk of acute rejection. 16 Therefore, a randomized trial is required to demonstrate the real treatment efficacy by comparing outcomes between patients with DSA and treated versus patients with DSA without treatment.
| S TUDY LIMITATI ON S
A control group made of eDSA + /no-treatment patients would have been more robust than a control group made of patients without eDSA, to demonstrate treatment effect. The choice of eDSA − patients instead of eDSA+/no-treatment patients was motivated by the fact that only few eDSA + patients were not treated, and that, according to the recent evidence in literature, [1] [2] [3] [4] [5] [6] [7] [8] 
| CON CLUS IONS
After lung transplantation, outcomes of treated patients with eDSA were similar to the outcomes of patients without eDSA.
These results were confirmed after matching and stratification into quintiles of propensity scores. Treated patients showed high antibody clearance, that persisted at follow-up end. However, further studies are required to demonstrate that IgAM therapy really improves outcomes and directly leads to eDSA clearance, since most of the eDSA + /no-treatment patients cleared eDSA spontaneously.
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